NBIX.NASDAQNeurocrine Biosciences INC
10-K: Neurocrine Biosciences Reports Strong INGREZZA Sales, Advances Pipeline in 2024
Sentiment:
Annual Results
Neurocrine Biosciences' 2024 10-K filing highlights strong INGREZZA sales, the launch of CRENESSITY, and progress across its neuropsychiatry and neurology pipeline.
Better than expectedINGREZZA net product sales for 2024 increased $477.5 million, or 26.0%, to $2.3 billion, reflecting strong underlying patient demand and improved gross-to-net dynamics.
Summary
- Neurocrine Biosciences reported INGREZZA net product sales of $2.3 billion for 2024, a 26% increase from 2023.
- The company launched CRENESSITY in the U.S. in December 2024 as a first-in-class treatment for classic congenital adrenal hyperplasia (CAH).
- Neurocrine is advancing its pipeline with Phase 3 studies for osavampator in major depressive disorder (MDD) and valbenazine for dyskinetic cerebral palsy.
- Positive Phase 2 data was announced for NBI-1117568 in schizophrenia and osavampator in MDD.
- The company expects to advance NBI-1117568 into Phase 3 development in the first half of 2025.
- Neurocrine settled convertible senior notes due May 15, 2024, in full in cash upon maturity.
- The company repurchased and retired 2.3 million shares of its common stock under an accelerated share repurchase (ASR) program.
- Neurocrine is transforming its research and development strategies to include the development of biologics, including peptides, antibodies and gene therapies.
- The company added more than 400 new employees to its team during 2024 and expects to add additional employees in 2025 with a focus on expanding its research and development organization.
Sentiment
Score: 8
Explanation: The document presents a positive outlook with strong financial performance and pipeline advancements. The company is growing and expanding its research and development efforts.
Positives
- Strong growth in INGREZZA sales indicates continued market acceptance and demand.
- The launch of CRENESSITY provides a new treatment option for CAH patients.
- Advancement of multiple pipeline programs into Phase 3 demonstrates progress in research and development.
- Positive Phase 2 data for NBI-1117568 and osavampator suggests potential for new treatments in neuropsychiatry.
- The company's financial position is strengthened by strong sales and effective capital management.
Negatives
- The company incurred $138.4 million in expenses related to the conversion of senior notes.
- The company reported an unrealized loss on equity investments of $37.1 million.
- The company faces intense competition from other pharmaceutical companies.
- The company is subject to government healthcare regulations and potential drug pricing controls.
Risks
- The company's success depends on the continued commercialization of INGREZZA and the successful launch of CRENESSITY.
- Clinical trials may be delayed or fail to demonstrate safety and efficacy.
- The company relies on third-party suppliers and manufacturers.
- The company may need additional capital in the future.
- The company is subject to healthcare reform and drug pricing measures.
Future Outlook
Neurocrine expects to add additional employees in 2025 with a focus on expanding its research and development organization and to advance NBI-1117568 into Phase 3 development in the first half of 2025.
Industry Context
The report highlights the competitive landscape in the biotechnology and pharmaceutical industries, with Neurocrine facing competition from companies like Teva Pharmaceuticals and others developing treatments for similar disorders.
Comparison to Industry Standards
- INGREZZA competes with AUSTEDO (deutetrabenazine), marketed by Teva Pharmaceuticals Industries, for the treatment of tardive dyskinesia in adults and chorea associated with Huntington's disease.
- CRENESSITY competes with high dose corticosteroid monotherapy which is the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive adrenocorticotropic hormone levels for patients with CAH.
- In the U.S. alone, there are more than two dozen companies manufacturing steroid-based products.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | Kevin Gorman, Ph.D. | Kyle Gano, Ph.D. | October 11, 2024 | Retirement |
Legal Proceedings
- In January 2025, Neurocrine filed suit in the United States District Court for the District of Delaware against Spruce Biosciences, Inc. (Spruce), seeking to invalidate one of Spruces patents.
- In addition, Neurocrine has initiated (1) administrative proceedings against other Spruce patents in the U.S. Patent Office, and (2) both judicial and administrative proceedings against Spruce patents in other jurisdictions.
Stakeholder Impact
- Shareholders: The company's strong financial performance and pipeline advancements are likely to positively impact shareholder value.
- Employees: The company's growth and expansion plans may create new job opportunities and career advancement prospects.
- Patients: The company's development of new treatments may provide hope for patients with neurological, neuropsychiatric, and neuroendocrine disorders.
Next Steps
- Advance NBI-1117568 into Phase 3 development in the first half of 2025.
- Continue commercialization of INGREZZA and CRENESSITY.
- Continue development of pipeline programs.
Key Dates
| Date | Description |
|---|---|
| January 1992 | Neurocrine Biosciences was originally incorporated in California. |
| May 1996 | Neurocrine Biosciences reincorporated in Delaware. |
| May 2017 | INGREZZA launched in the U.S. as the first FDA-approved drug for the treatment of tardive dyskinesia. |
| August 2018 | AbbVie launched ORILISSA in the U.S. for the treatment of endometriosis. |
| June 2020 | AbbVie launched ORIAHNN in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids. |
| June 2022 | MTPC launched DYSVAL in Japan for the treatment of tardive dyskinesia. |
| February 2023 | A once-daily dosing of AUSTEDO (AUSTEDO XR) was introduced. |
| August 2023 | INGREZZA launched for the treatment of chorea associated with Huntington's disease. |
| September 2024 | Expanded INGREZZA psychiatry and long-term care sales teams. |
| October 11, 2024 | Kevin Gorman, Ph.D., retired as the Company's President and Chief Executive Officer and Kyle Gano, Ph.D., succeeded Dr. Gorman in the CEO role. |
| October 2024 | Board of Directors authorized a share repurchase program to repurchase up to $300 million of the Company's common stock. |
| December 2024 | FDA approved and launched CRENESSITY capsules and oral solution as an adjunctive treatment of CAH. |
| January 2025 | HHS announced its selection of fifteen additional drugs covered under Part D for negotiation in 2025 (for initial price applicability year 2027). |
| January 2025 | The Centers for Medicare & Medicaid Services (CMS) implemented those provisions of the IRA establishing a new Medicare Part D manufacturer discount program. |
| January 2025 | Neurocrine was notified that INGREZZA qualifies for the small biotech exception, which provides an exemption from selection for price negotiation until 2027. |
| January 2025 | Amended strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize osavampator. |
| January 2025 | Provided Idorsia Pharmaceuticals Ltd. with written notice of termination of the license agreement to develop and commercialize NBI-827104. |
| First quarter 2025 | Initiating Phase 1 clinical study of NBI-921355. |
| First half of 2025 | Expect to advance NBI-1117568 into Phase 3 development. |
| February 2025 | The purchase period for the ASR transaction ended. |
Keywords
INGREZZA, CRENESSITY, Neurocrine, valbenazine, crinecerfont, tardive dyskinesia, CAH, Huntington's disease, clinical trials, biopharmaceutical, neuroscience, FDA, sales, pipeline, research and development
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.